» Articles » PMID: 11376111

Disrupted Amino- and Carboxyl-terminal Interactions of the Androgen Receptor Are Linked to Androgen Insensitivity

Overview
Journal Mol Endocrinol
Date 2001 May 29
PMID 11376111
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

We have compared the functional consequences of seven single-point mutations in the ligand-binding domain (LBD) of the androgen receptor (AR). The mutations span helices 3 to 11 and are present in patients suffering from androgen insensitivity syndromes (AIS) and other male-specific disorders. The mutants, except M742V, bound to androgen response elements in vivo and in vitro and showed a testosterone-dependent conformational change. With regard to functional activity, the mutant M742V had severely blunted ability to transactivate or exhibit the androgen-dependent amino/carboxyl-terminal (N/C) interaction; mutants F725L, G743V, and F754L showed reduced transactivation potential and attenuated N/C interaction; and mutants V715M, R726L, and M886V had minor functional impairments. The mutants belonging to the first two groups also displayed reduced response to coexpressed GRIP1. In addition, mutations of amino acids M894 and A896 in the putative core activation domain 2 (AF2) in helix 12 confirmed that this helix is important for N/C interactions. Thus, amino acids located between helices 3 and 4 (F725 and R726), in helix 5 (M742, G743, and F754), and in helix 12 (M894 and A896) play critical roles in mediating the N/C interaction of AR. The data also show that disrupted N/C interaction is a potential molecular abnormality in AIS cases in which LBD mutations have not resulted in markedly impaired ability to bind androgen.

Citing Articles

IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth.

Lin G, Tian F, Yu Q, Weng X, Yu N, Zhang F Oncogene. 2024; 43(49):3598-3616.

PMID: 39424989 DOI: 10.1038/s41388-024-03169-z.


N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review.

Chen Y, Lan T Front Pharmacol. 2024; 15:1451957.

PMID: 39359255 PMC: 11444995. DOI: 10.3389/fphar.2024.1451957.


A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance.

Alegre-Marti A, Jimenez-Panizo A, Martinez-Tebar A, Poulard C, Peralta-Moreno M, Abella M Sci Adv. 2023; 9(11):eade2175.

PMID: 36921044 PMC: 10017050. DOI: 10.1126/sciadv.ade2175.


Four novel mutations in the androgen receptor gene from Vietnamese patients with androgen insensitivity syndrome.

Nguyen T, Nguyen D, Kim L, Thi T, Nguyen T, Tran N Genes Genomics. 2022; 45(4):467-474.

PMID: 35445939 DOI: 10.1007/s13258-022-01249-6.


Novel compound variants of the AR and MAP3K1 genes are related to the clinical heterogeneity of androgen insensitivity syndrome.

Cheng Y, Sun Y, Ji Y, Jiang D, Teng G, Zhou X Biosci Rep. 2020; 40(5).

PMID: 32338288 PMC: 7953519. DOI: 10.1042/BSR20200616.